Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from ICON7 phase III trial

This study aims to describe the health-related quality-of-life (QoL) outcomes from ICON7.   ICON7 is a randomised, multicentre, open-label phase III trial in women with International Federation of Gynecology and Obstetrics (FIGO) high-risk stage I to IV epithelial ovarian cancer who had had surgery to debulk the tumour. They were randomised to receive either six cycles of standard chemotherapy (total 18 weeks) with carboplatin (AUC 5 or 6) and paclitaxel (175 mg/m2) alone (n= 764) or with bevacizumab (7.5 mg/kg) given intravenously with chemotherapy (n= 764) and ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news